Table 1. Predisposing conditions for NJI in adults (other than recent joint procedures). *P*-value, males cf females.

| Condition ^a | Adults (≥18 | Male | Female | P-value |
|--|-------------|-----------|----------|---------|
| | years) | N=174 | N=85 | |
| | N=259 | | | |
| Osteoarthritis | 69 (27) | 39 (22) | 30 (35) | 0.03 |
| Ischemic heart disease | 35 (13.5) | 25 (14) | 10 (12) | 0.7 |
| Immunosuppressive therapy ^b | 32 (12) | 15 (8.5) | 17 (20) | 0.01 |
| Diabetes mellitus type 2 | 30 (12) | 21 (12) | 9 (10.5) | 0.8 |
| Blunt trauma to joint | 27 (10) | 22 (12.5) | 5 (6) | 0.1 |
| Chronic renal failure | 25 (10) | 18 (10) | 7 (8) | 0.7 |
| Crystal arthropathy ^c | 20 (8) | 15 (8.5) | 5 (6) | 0.6 |
| Heart failure | 18 (7) | 15 (8.5) | 3 (3.5) | 0.2 |
| Psoriasis | 16 (6) | 12 (7) | 4 (5) | 0.6 |
| Rheumatoid arthritis | 16 (6) | 6 (3) | 10 (12) | 0.01 |
| Alcohol abuse | 12 (5) | 8 (4.5) | 4 (5) | 1 |
| Chronic liver disease d | 11 (4) | 6 (3) | 5 (6) | 0.3 |
| Malignancy ^e | 11 (4) | 7 (4) | 4 (5) | 0.8 |
| Injection drug use | 9 (3.5) | 4 (2) | 5 (6) | 0.2 |
| Psoriatic arthritis | 7 (3) | 2 (1) | 5 (6) | 0.04 |
| Polymyalgia rheumatica | 4 (1.5) | 1 (0.5) | 3 (3.5) | 0.1 |
| HIV | 1 (0.4) | 0 | 1 (1) | 0.3 |
| | | | | |

Data are no/No (%). P- value compares males and females, bolded where statistically significant.

^a Total number of cases with predisposing conditions: 212 adults, some patients had >1 condition.

^b Some patients were taking >1 immunosuppressive drug; Methotrexate 15, glucocorticoids 25, Sulfasalazine 1,

Hydroxychloroquine 1, Mycophenolic acid 1, Etanercept 1, Infliximab 3, other chemotherapeutic agents for cancer: 3.

^c Gout 17 cases, calcium pyrophosphate disease 3 cases.

Table 2. Empiric and definitive antimicrobial therapy for septic arthritis in Iceland 2003-2017

| Antibiotic ^a | Children (<18 | | Adults (≥18 years) | Adults (≥18 years) | |
|-------------------------|-----------------|-------------|--------------------|--------------------|--|
| | years) | Definitive | Empiric therapy | Definitive | |
| | Empiric therapy | therapy | | therapy | |
| Cloxacillin | 33/40 (82.5) | 24/40 (60) | 166/256 (65) | 127/250 (51) | |
| Cefuroxime | 4/40 (10) | 5/40 (12.5) | 0 | 0 | |
| Cefazolin | 1/40 (2.5) | 2/40 (5) | 24/256 (9) | 22/250 (9) | |
| Vancomycin | 0 | 0 | 18/256 (7) | 25/250 (10) | |
| Penicillin | 1/40 (2.5) | 2/40 (5) | 16/256 (6) | 29/250 (12) | |
| Ceftriaxone | 0 | 3/40 (7.5) | 14/256 (6) | 29/250 (12) | |
| Clindamycin | 0 | 2/40 (5) | 11/256 (4) | 9/250 (4) | |
| Ampicillin | 1/40 (2.5) | 0 | 4/256 (2) | 6/250 (2) | |
| Other ^b | 0 | 2/40 (5) | 3/256 (1) | 10/250 (4) | |
| Total ^c | 40 | 40 | 256 | 257 | |

Data are no/No (%).

^d Nine patients had hepatitis C, two patients had both hepatitis C and B, three patients had cirrhosis.

^e Solid tumors 6 cases, hematologic malignancy 5 cases.

^a Information on empiric therapy and definitive therapy was available in all children and 99% (256/259) and 96,5% (250/259) of adult cases respectively.

^b Definitive therapy: Amoxicillin-clavulanate 1, ceftazidime 2, ciprofloxacin 6, imipenem 1, linezolid 2, rifampicin 1 case (used with ceftriaxone).

 $^{^{\}rm c}\,\mbox{In seven}$ adult cases 2 antibiotics met criteria for definitive treatment.

Table 3. Treatment and outcome for septic arthritis in Iceland 2003-2017. P-value, children cf adults.

| Treatment | Children (<18 years) | Adults (≥18 years) | <i>P</i> -value |
|--|----------------------|--------------------|-----------------|
| Duration of parenteral therapy (days) ^a | 13.5 | 29 | p<0.0001 |
| Surgical management: | | | |
| Closed needle aspiration | 6/40 (15) | 205/259 (79) | p<0.0001 |
| Open or arthroscopic surgery | 15/40 (37.5) | 107/259 (41) | p=0.7 |
| Outcomes: | | | |
| Relapse | 0 | 12/259 (4.6) | - |
| Amputation ^b | 0 | 2/259 (0.8) | - |
| DROM ^c | 9/36 (25) | 133/175 (76) | p<0.0001 |
| Insertion of prosthetic joint ^d | 0 | 24/259 (9) | - |
| 30-day mortality | 0 | 14/259 (5.4) | - |

Data are no/No (%). *P* -value compares children and adults, bolded where statistically significant. Median values are shown for duration of parenteral treatment.

^a Information concerning the length of intravenous treatment was noted in 81% (241/299) of all cases. Adults: IQR=21-42 days, children: IQR=10-28,5 days

^b One patient had a history of diabetes with chronic leg ulcers and the other a history of peripheral vascular disease with an infected femoropopliteal bypass.

^c DROM: decreased range of motion at discharge or first follow up appointment. Information was found in 67.5% of adult cases (175/259) and 90% of children (36/40).

^d Average time from diagnoses to insertion of prosthetic joint was 3,5 years, median time 2,5 years. All were placed within 9 years of infection.




Figure 1: Iatrogenic infections as part of the total number of joint infections per year. SA: septic arthritis.




Figure 2: Comparison of iatrogenic infections in Iceland, 1990-2002 and 2003-2017. Incidence numbers are shown above each column as per 100.000 residents per year.